These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28346967)

  • 21. Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials.
    Tarango C; Schulman S; Betensky M; Goldenberg NA
    Expert Rev Hematol; 2018 Jan; 11(1):37-44. PubMed ID: 29183221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
    Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
    Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Venous Thromboembolism With New Anticoagulant Agents.
    Becattini C; Agnelli G
    J Am Coll Cardiol; 2016 Apr; 67(16):1941-55. PubMed ID: 27102510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel or non-vitamin K antagonist oral anticoagulants and the treatment of cancer-associated thrombosis.
    Wu C; Lee AY
    Semin Thromb Hemost; 2015 Mar; 41(2):237-43. PubMed ID: 25682086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
    Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
    J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin for prevention and treatment of venous thromboembolism.
    Becattini C; Agnelli G
    Blood Rev; 2014 May; 28(3):103-8. PubMed ID: 24745726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran for the treatment of venous thromboembolism.
    Schellong SM
    Expert Rev Hematol; 2015 Aug; 8(4):413-25. PubMed ID: 26111881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
    Bauersachs R
    Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants.
    Lyle CA; Sidonio RF; Goldenberg NA
    Curr Opin Pediatr; 2015 Feb; 27(1):18-25. PubMed ID: 25564186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Direct Oral Anticoagulants in the Management of Anticoagulation.
    Thakkar RN; Rathbun SW; Wright SM
    South Med J; 2017 Apr; 110(4):293-299. PubMed ID: 28376529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
    Merli G; Spyropoulos AC; Caprini JA
    Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism.
    Knepper J; Ramacciotti E; Wakefield TW
    Phlebology; 2011 Feb; 26(1):3-7. PubMed ID: 21239724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism.
    Granziera S; Hasan A; Cohen AA
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):209-21. PubMed ID: 26329910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of thrombosis in children and neonates: practical use of anticoagulants in children.
    Monagle P; Newall F
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):399-404. PubMed ID: 30504338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.
    Zalpour A; Oo TH
    Drug Des Devel Ther; 2014; 8():2181-91. PubMed ID: 25395835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.